FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog of the Federal Food, Drug, and Cosmetic Act (FDCA).* BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved Forward progress